We are live on
!
Find out more
Arrowstreet Capital Portfolio holdings
AUM
$185B
1-Year Est. Return
39.58%
This Fund
S&P 500
This Quarter
Est. Return
+8.74%
1 Year Est. Return
+39.58%
3 Year Est. Return
+145.48%
5 Year Est. Return
+192.07%
10 Year Est. Return
+749.68%
AUM
$19.4B
AUM Growth
+$2.92B
(+18%)
Cap. Flow
+$1.81B
Cap. Flow
% of AUM
9.28%
Top 10 Holdings %
Top 10 Hldgs %
20.62%
Holding
1,394
New
273
Increased
343
Reduced
316
Closed
453
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$694M |
| 2 |
Philip Morris
PM
|
+$316M |
| 3 |
Johnson & Johnson
JNJ
|
+$315M |
| 4 |
Merck
MRK
|
+$303M |
| 5 |
APC
Anadarko Petroleum
APC
|
+$235M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$248M |
| 2 |
Micron Technology
MU
|
+$212M |
| 3 |
RAD
Rite Aid Corporation
RAD
|
+$196M |
| 4 |
Comcast
CMCSA
|
+$165M |
| 5 |
GSK
GSK
|
+$149M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.45% |
| 2 | Energy | 18.88% |
| 3 | Healthcare | 17.92% |
| 4 | Financials | 10.19% |
| 5 | Consumer Staples | 7.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
726
Argan
AGX
$8.34B
| $931K | ﹤0.01% |
+24,956
| New | +$749K |
|
727
iShares S&P India Nifty 50 Index Fund
INDY
$568M
| $930K | ﹤0.01% |
+32,119
| New | +$881K |
|
728
US Physical Therapy
USPH
$1.21B
| $930K | ﹤0.01% |
27,195
+15,103
| +125% | +$487K |
|
|
EGOV
729
DELISTED
NIC Inc
EGOV
| $921K | ﹤0.01% |
+58,099
| New | +$1.01M |
|
730
Teekay
TK
$984M
| $917K | ﹤0.01% |
14,726
+7,648
| +108% | +$442K |
|
731
Booz Allen Hamilton
BAH
$9.2B
| $903K | ﹤0.01% |
42,529
-28,405
| -40% | -$642K |
|
|
RLD
732
DELISTED
REALD INC COM STK
RLD
| $902K | ﹤0.01% |
+70,678
| New | +$819K |
|
733
NETSCOUT
NTCT
$2.8B
| $897K | ﹤0.01% |
+20,230
| New | +$786K |
|
|
WW
734
DELISTED
WW International
WW
| $889K | ﹤0.01% |
44,072
-209,136
| -83% | -$4.48M |
|
|
JRN
735
DELISTED
JOURNAL COMMUNICATIONS INC CL-A
JRN
| $885K | ﹤0.01% |
99,742
+48,974
| +96% | +$404K |
|
|
KND
736
DELISTED
Kindred Healthcare
KND
| $883K | ﹤0.01% |
+38,210
| New | +$934K |
|
|
ANW
737
DELISTED
Aegean Marine Petroleum Network
ANW
| $878K | ﹤0.01% |
87,065
+26,347
| +43% | +$258K |
|
|
NXTM
738
DELISTED
NxStage Medical Inc.
NXTM
| $870K | ﹤0.01% |
+60,561
| New | +$791K |
|
739
Jazz Pharmaceuticals
JAZZ
$16.7B
| $868K | ﹤0.01% |
5,903
-30,148
| -84% | -$4.18M |
|
740
FirstCash
FCFS
$8.86B
| $863K | ﹤0.01% |
+14,983
| New | +$775K |
|
|
SGEN
741
DELISTED
Seagen Inc. Common Stock
SGEN
| $860K | ﹤0.01% |
+22,471
| New | +$850K |
|
742
AutoNation
AN
$6.96B
| $855K | ﹤0.01% |
+14,328
| New | +$793K |
|
|
MPO
743
DELISTED
MIDSTATES PETE CO INC COM NEW
MPO
| $851K | ﹤0.01% |
11,777
+6,215
| +112% | +$365K |
|
744
Westlake Corp
WLK
$10B
| $848K | ﹤0.01% |
10,121
-28,859
| -74% | -$2.16M |
|
745
Baytex Energy
BTE
$2.94B
| $846K | ﹤0.01% |
18,300
-84,671
| -82% | -$3.6M |
|
|
ORBK
746
DELISTED
Orbotech Ltd
ORBK
| $844K | ﹤0.01% |
55,592
-49,793
| -47% | -$750K |
|
747
Scansource
SCSC
$1.13B
| $841K | ﹤0.01% |
+22,073
| New | +$842K |
|
748
Altisource Portfolio Solutions
ASPS
$64.6M
| $837K | ﹤0.01% |
+913
| New | +$815K |
|
|
STNR
749
DELISTED
STEINER LEISURE LTD
STNR
| $832K | ﹤0.01% |
19,212
-22,815
| -54% | -$963K |
|
750
ON Semiconductor
ON
$19.2B
| $826K | ﹤0.01% |
90,425
-1,103,740
| -92% | -$10.1M |
|
Similar funds
VGA
Arrowstreet Capital's Q2 2014 Portfolio in Review
As of Q2 2014, Arrowstreet Capital held 1,394 positions worth $19.4B, up 18% from $16.5B the previous quarter. Its ten largest holdings account for 21% of the portfolio.
Arrowstreet Capital deployed $1.81B of net new capital in Q2 2014, opening 273 new positions and adding to 343 existing holdings. Its largest new stake was Johnson & Johnson: 3,117,484 shares worth $326M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 22% a quarter earlier, followed by Energy and Healthcare.
On the sell side, the largest reduction was Gilead Sciences, an estimated $248M trimmed.
- Arrowstreet Capital's largest Q2 2014 buy was Johnson & Johnson: 3,117,484 shares worth $326M.
- Arrowstreet Capital added most to Apple in Q2 2014, an estimated $694M increase.
- Arrowstreet Capital's biggest Q2 2014 reduction was Gilead Sciences, cutting an estimated $248M.
- Arrowstreet Capital fully exited Comcast in Q2 2014, selling an estimated $165M.
- Arrowstreet Capital's ten largest holdings make up 21% of its $19.4B portfolio in Q2 2014.
- Arrowstreet Capital opened 273 new positions and closed 453 in Q2 2014.
- Arrowstreet Capital's portfolio value rose 18% quarter-over-quarter to $19.4B.
Based on Arrowstreet Capital's 13F filing for Q2 2014, filed 14 Aug 2014.